Puma Biotechnology (PBYI) Total Current Liabilities (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Total Current Liabilities came in at $59.7 million in Q1 2026, down 31.07% YoY from $86.7 million in Q1 2025, and down 26.48% on a QoQ basis from $81.3 million in Q4 2025.
Puma Biotechnology (PBYI) Total Current Liabilities (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 16 years of Total Current Liabilities data on file, last reported at $59.7 million in Q1 2026.
- Quarterly Total Current Liabilities fell 31.07% year-over-year to $59.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.7 million (down 31.07% YoY) and the FY2025 annual result came in at $81.3 million, down 15.46% from the prior year.
- Total Current Liabilities retreated to $59.7 million in Q1 2026, from $81.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $110.4 million in Q3 2024 to a low of $48.2 million in Q1 2023.
- A 5-year average of $79.0 million and a median of $79.1 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 58.79% — and 2024, when it surged 103.77%.
- Tracing PBYI's Total Current Liabilities over 5 years: stood at $77.5 million in 2022, then climbed by 28.26% to $99.4 million in 2023, then fell by 3.29% to $96.1 million in 2024, then retreated by 15.46% to $81.3 million in 2025, then decreased by 26.48% to $59.7 million in 2026.
- The last three Total Current Liabilities figures came in at $59.7 million (Q1 2026), $81.3 million (Q4 2025), and $82.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 49.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.83 Mn |
| Mar 31, 2026 | 59.74 Mn |
| Dec 31, 2025 | 81.25 Mn |
| Sep 30, 2025 | 82.73 Mn |
| Jun 30, 2025 | 79.10 Mn |
| Mar 31, 2025 | 86.66 Mn |
| Dec 31, 2024 | 96.11 Mn |
| Sep 30, 2024 | 110.40 Mn |
| Jun 30, 2024 | 104.30 Mn |
| Mar 31, 2024 | 98.19 Mn |
| Dec 31, 2023 | 99.38 Mn |
| Sep 30, 2023 | 67.36 Mn |
| Jun 30, 2023 | 60.29 Mn |
| Mar 31, 2023 | 48.19 Mn |
| Dec 31, 2022 | 77.48 Mn |
| Sep 30, 2022 | 59.99 Mn |
| Jun 30, 2022 | 56.83 Mn |
| Mar 31, 2022 | 74.79 Mn |
| Dec 31, 2021 | 109.59 Mn |
| Sep 30, 2021 | 116.26 Mn |